Ophthalmology 360
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Photo Contest
    • Industry Council
    • Advisory Board

What are you looking for?

  • Anterior Segment
  • Cataract
  • Cornea and External Disease
  • Diabetic Macular Edema
  • Dry Eye
  • Early Onset Cataracts
  • Exclusives
  • General
  • Geographic Atrophy
  • Glaucoma
  • Industry News
  • Inherited Retinal Disease
  • IOLs
  • Neurotrophic Keratitis
  • Ocular Surface Disease
  • Oculoplastics
  • Optometry
  • Pediatrics
  • Practice Management
  • Presbyopia
  • Refractive Surgery/Vision Correction
  • Residents & Young Ophthalmologists
  • Retina
  • Retina Care 360
  • Retinopathy of Prematurity
  • Spotlight Series
  • The Interventional Glaucoma Project
  • The Ophthalmic Project
  • Trending Topics
2nd Annual Photo Contest - Enter Here!
Ophthalmology 360
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Photo Contest
    • Industry Council
    • Advisory Board
Home > Geographic Atrophy > Deep learning approach may help expedite screening of late-stage AMD
  • Geographic Atrophy

Deep learning approach may help expedite screening of late-stage AMD

Ophthalmology 360

Due to the large amount of data generated from optical coherence tomography angiography (OCTA) used in the diagnosis of age-related macular degeneration (AMD), utilizing artificial intelligence to analyze the data is needed.

A deep learning (DL) approach utilizing a combination of OCTA, OCT structure, 2D b-scan flow images, and high definition (HD) 5-line b-scan cubes can be used to detect AMD class as well as determine non-AMD vs. non-neovascular (NNV) AMD vs. NV AMD.

Multimodal data were used as input to 2D-3D Convolutional Neural Networks (CNNs).

Choroidal neovascularization and geographic atrophy were identified as important biomarkers for AMD for CNNs and experts. CNNs predict biomarkers with accuracy up to 90.2% (positive-predictive-value up to 75.8%).

“Detection of AMD and its biomarkers from OCTA data via CNNs has tremendous potential to expedite screening of early and late-stage AMD patients,” the authors concluded.

Reference
Thakoor KA, Yao J, Bordbar D, et al. A multimodal deep learning system to distinguish late stages of AMD and to compare expert vs. AI ocular biomarkers. Sci Rep. 2022;12(1):2585. doi: 10.1038/s41598-022-06273-w. PMID: 35173191; PMCID: PMC8850456.

This content is independent editorial sponsored by Astellas. Astellas had no input in the development of this content.

Share

Related Content

  • Cataract

Cataract surgery linked to modest increase in neovascular AMD conversion risk

  • General

Preserflo associated with fewer complications than Xen63 in glaucoma surgery

  • Geographic Atrophy

Geographic atrophy linked to vision loss, higher healthcare costs, and fall risk

  • General

Glaucoma may signal complications in intraocular cancers, review suggests

  • General

XEN63 Gel Stent shows sustained glaucoma control over 3 years

  • Geographic Atrophy

Spotlight on IZERVAY®

Share

Editor's Picks

  • Neurotrophic Keratitis

Topical insulin shows real-world benefit in neurotrophic keratopathy

  • Retina

GLP-1 RAs have protective effects against AMD

  • Retina

Four-month injection intervals appear safe for long-term stable nAMD

Advisory Board

Saad Ahmad, MD

Ahmad A. Aref, MD, MBA

Roomasa Channa, MD

David Chow, MD, FRCS(C)

Sally L. Baxter, MD, MSc

Neel R. Desai, MD

Nadia Haqqie, MD

Simon Fung, MD, FRCOphth

Sumit Garg, MD

Ross Lakhanpal, MD, FACS

Sanjai Jalaj, MD

Anton Kolomeyer, MD, PhD

Shan Lin, MD

Steven R. Sarkisian, Jr., MD

See All
Ophthalmology 360

Ophthalmology 360® is a dynamic digital platform dedicated to advancing the field of eye care.

Get to Know Us

  • Home
  • About Us
  • Media Partners
  • Advertising Policy
  • Our Advisory Board

Sign up for our Newsletter

Sign up for our Newsletter to get our newest articles instantly!

  • Privacy Policy
  • Advertising Policy
  • Medical Disclaimer
IHM Logo

2026 Ophthalmology 360 is a trademark of International Healthcare Media, LLC. All rights reserved

  • MedJournal360 Icon
  • RareDisease360 Icon
  • MyHero360 Icon
  • Optometry360 Icon
  • Ophtalmology360 Icon